Hikma And CanariaBio Sign Exclusive Licensing Agreement To Bring Oregovomab To The Middle East And North Africa

By Emmanuel Oluebube, Bureau Chief, UK

The multinational pharmaceutical company, Hikma Pharmaceuticals PLC(Hikma), today announced  an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the terms of the agreement, Hikma has an exclusive license to commercialise Oregovomabin 18Middle East and North Africa (MENA) countries. 

Oregovomab is a murine monoclonal antibody and a first-in-class anti-CA125 immunotherapy drug candidate.It is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer. Oregovomab has obtained Orphan Drug Designations from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

“Ovarian cancer is ranked as the eighth most common cancer in women globally and the first-line treatment for this disease has not changed for many years.We have been actively expanding our oncology portfolio through R&D and in-licensing, in order to address unmet medical needs in different types of cancer and bring renewed hope to cancer patients in the MENA region,” said Hikma’s Executive Vice Chairman and President of MENA Mazen Darwazah. “We believe Oregovomab can potentially improve the treatment outcomes for patients with advanced primary ovarian cancer. We are excited about the collaboration with CanariaBio as it willbring hope to our cancer patients in MENAand strengthen our oncology portfolio.”